最後更新 進階搜尋 返回首頁 登出 聯絡我們
  目前線上人數: 789
Antidotes for intoxication
Antihistamines
Antimicrobial agents
Antineoplastic agent
Cardiovascular agents
Drugs action on the central nervous system
Gastrointestinal agents
Respiratory system agents
Metabolic and nutrient agents
Hematological agents
Hormones,Synthetic substitutes and hormone antagon
Genital system agents
Urinary system agents
Enzymes
Immunological agents
Diagnostic agents
Pediatric perparations
Dermatological preparations
Miscellaneous
EXTERNAL
others
緊急採購藥品
新藥介紹 / Metabolic and nutrient agents / Liraglutide Injection
Liraglutide Injection
2013-03-07    彰基藥學部藥品管理組       點選: 529
Victoza

Supply: 6mg/ml; 3ml/pen                                     <<MILIG>>    

Description: Victoza is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist which mimics 97% amino acid sequence to endogenous human GLP-1 (7 to 37), bind to the GLP-1 receptor for treatment of type 2 diabetic melliitus in combination with metformin, and/or sulphonylurea in patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Action :  Liraglutide can increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Liraglutide administration results in decreases in hemoglobin A1c by approximately 1%.

Pharmacokinetics: Bioavailability: 55%; half-life:13 hrs; Tmax: 8-12 hrs; elimination: renal 6%; feces 5%; clearance: 1.2 L/hr.

Indication: 第二型糖尿病。

1.       當患者已接受metforminsulphonylurea單一治療至最大可忍受劑量仍未達理想血糖控制時,與metforminsulphonylurea併用。

2.       或當患者已接受metformin加上sulphonylureametformin加上thiazolidinedione兩種藥物治療仍未達理想血糖控制時,與metformin加上sulphonylureametformin加上thiazolidinedione併用。

健保規範 :

1.限用於已接受過最大耐受劑量的metformin/sulfonylurea類藥物仍無法理想控制血糖之第二型糖尿病患者。

2.本藥品不得與insulinDPP-4抑制劑(如sitagliptin成分)等藥物併用。

院內規範:

1. 第二型糖尿病患者,若已經使用適當劑量的Metformin或一種以上的口服降血糖藥物(包括Metformin, sulfonylurea,TZD),而仍無法達到良好的血糖控制者(HbA1C7.5%),且符合下列條件之一者,可開始使用Victoza
(1)
無其他代謝疾病之中度肥胖者 (BMI > 30 kg/m2)
(2)
輕度肥胖 (27kg/m2 < BMI =< 30 kg/m2)合併有其他心血管疾病風險者,或經臨床醫師判定不適用胰島素者。

2. 下列情況不適用Victoza
(1)
第一型糖尿病患者。
(2)
尚未使用任何口服降血糖藥物的第二型糖尿病患者
(3)
具罹患胰臟炎高風險者。
(4)
個人或家族有甲狀腺髓質癌(Medullary thyroid carcinoma )病史或有第2
型多發性內分泌腫瘤(Multiple Endocrine Neoplasia type 2)患者。

3. 限內分泌新陳代謝科、減重中心醫師使用。

4. 第一次開立Victoza時必須轉介至糖尿病衛教中心(二樓39),由衛教護理師向患者解釋Victoza使用說明書的內容。

Dosage and Administration: SC, without regard to meals.

  Initial, 0.6 mg/day for one week; Maintenance,1.2 mg/day. If optimal glycemic response not achieved, may increase to 1.8 mg/day ( MAX).

Dosage in Renal impairment: none

Dosage in liver disease: none

Adverse drug reaction:

More frequent: hypoglycemia; diarrhea; nausea; vomiting

Less frequent: constipation; upper respiratory infection; headache; hyperbilirubinemia ; Injection site reactions; antiliraglutide antibodies.

Rare: acute renal failure; angioedema; anaphylactic reactions; chronic renal failure exacerbation; dehydration; hypersensitivity reactions; hypoglycemia (most reports in patients receiving combination therapy); pancreatitis (including acute, chronic, and necrotizing); papillary thyroid carcinoma; pruritus; rash; thyroid C-cell hyperplasia  

Contraindication: Contraindicated use in patient with hypersensitivity to liraglutide or any product component.; medullary thyroid carcinoma (MTC) ; multiple endocrine neoplasia syndrome type 2 (MEN 2).

CautionCaution use in patient with thyroid C-cell hyperplasia; acute renal failure; worsening of chronic renal failure; angioedema; concomitant use of insulin secretagogues (eg, sulfonylureas) may increased risk of hypoglycemia; pancreatitis.

Storage & Stability: 2- 8

Note:

1.       給藥時間,可在任何時間每日投予一次。

2.       以皮下方式注射於大腿腹部或上臂。

3.       開封後冷藏於2- 8°C或置於室溫15 - 30避光環境中,最多可保存30天。

Pregnancy Category: C

Breastfeeding: Infant risk cannot be ruled out.

Reference:

1. 2013 Uptodate

2. MICROMEDEX(R) Healthcare Series Vol. 147 expires 2010.   

3. Drug package Insert.

4. 2013 DynaMed

責任編輯: racer
 列印此文章
Copyright © 2004-01 新藥介紹
Edited By CCHP Racer